Article Text

PDF
Clinical trials of endothelin antagonists in heart failure: publication is good for the public health
  1. N F Kelland,
  2. D J Webb
  1. Clinical Pharmacology Unit, Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, Edinburgh, UK
  1. Correspondence to:
    D J Webb
    Clinical Pharmacology Unit, Centre for Cardiovascular Science, University of Edinburgh, Queen’s Medical Research Institute, 3rd Floor East Room E3.22, 47 Little France Crescent, Edinburgh EH16 4TJ, UK; d.j.webb{at}ed.ac.uk

Abstract

The failure of endothelin antagonists to show benefit in heart failure cannot be understood until all the clinical trials are fully published

  • CHF, chronic heart failure
  • EARTH, Endothelin A Receptor Antagonist Trial in Heart Failure
  • HEAT, Haemodynamic and Neurohumoral Effects of Selective Endothelin A Receptor Blockade in Chronic Heart Failure
  • NYHA, New York Heart Association

Statistics from Altmetric.com

Footnotes

  • Competing interests: NFK is a British Heart Foundation Junior Research Fellow (FS/03/006/15108) and has received grants to attend conferences from Merck, Pfizer and Sanofi. DJW has, in the past, advised Abbott, Actelion, Roche and Bristol-Myers Squibb on the development of ET antagonists, and has undertaken clinical studies using ET antagonists with Astra-Zeneca, Bristol-Myers Squibb, Encysive, Takeda and Vanguard. NFK and DJW have received donations of ET antagonists from Abbott Pharmaceuticals for use in their preclinical research.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.